[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Rodriguez et al., 2016 - Google Patents

Pediatric coagulation disorders

Rodriguez et al., 2016

View PDF
Document ID
10217309680358508690
Author
Rodriguez V
Warad D
Publication year
Publication venue
Pediatrics in review

External Links

Snippet

Hemostasis in the pediatric patient evolves as the child grows and matures, and normal adult laboratory values are not often the norm for a child. This article provides a summary of the pathophysiology of hemostasis (eg, bleeding and thrombosis disorders) and reviews the …
Continue reading at renaissance.stonybrookmedicine.edu (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Similar Documents

Publication Publication Date Title
Ferriero et al. Management of stroke in neonates and children: a scientific statement from the American Heart Association/American Stroke Association
Williams et al. The investigation and management of neonatal haemostasis and thrombosis
Zimmerman et al. Hemophilia: in review
Revel-Vilk The conundrum of neonatal coagulopathy
Rodriguez et al. Pediatric coagulation disorders
Will Neonatal haemostasis and the management of neonatal thrombosis
Monagle et al. Hemostasis in neonates and children: pitfalls and dilemmas
Schechter et al. Unfractionated heparin dosing in young infants: clinical outcomes in a cohort monitored with anti‐factor Xa levels
Streif et al. Venous thromboembolic events in pediatric patients: diagnosis and management
Raffini Thrombophilia in children: who to test, how, when, and why?
Kenet et al. Venous thromboembolism in neonates and children
Jaffray et al. The bleeding newborn: a review of presentation, diagnosis, and management
Hanmod et al. Neonatal hemostatic disorders: issues and challenges
Sahud et al. Platelet dysfunction—differentiation of a newly recognized primary type from that produced by aspirin
Andrew et al. The prevention and treatment of thromboembolic disease in children: a need for thrombophilia programs
Kenet et al. Hemostasis in the very young
Sidlik et al. Assessment of functional fibrinolysis in cord blood using modified thromboelastography
Fabes et al. Pro‐coagulant haemostatic factors for the prevention and treatment of bleeding in people without haemophilia
Truong et al. Platelet inhibition in shunted infants on aspirin at short and midterm follow-up
Revel-Vilk et al. Thromboembolic diseases of childhood
Motta et al. Clinical use of fresh-frozen plasma and cryoprecipitate in neonatal intensive care unit
Bhatt et al. How to use unfractionated heparin to treat neonatal thrombosis in clinical practice
Moiseiwitsch et al. Neonatal coagulopathies: A review of established and emerging treatments
Carpenter et al. Evaluating for suspected child abuse: conditions that predispose to bleeding
Morley Management of acquired coagulopathy in acute paediatrics